Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication

Commentary 10.1172/JCI130755

Antiobesogenic effects of central GIPR antagonism

Jessica T.Y. Yue1 and Tony K.T. Lam2,3,4,5

1Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.

2Toronto General Hospital Research Institute, University Health Network (UHN), Toronto, Ontario, Canada.

3Department of Physiology,

4Department of Medicine, and

5Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.

Address correspondence to: Jessica Yue, 7-21 Medical Sciences Building, Department of Physiology, University of Alberta, Edmonton, Alberta, Canada T6G2H7. Phone: 780.248.5804; Email: jessica.yue@ualberta.ca. Or to: Tony Lam, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 705, Toronto, Ontario, Canada M5G1L7. Phone: 416.581.7880; Email: tony.lam@uhnres.utoronto.ca.

Find articles by Yue, J. in: JCI | PubMed | Google Scholar

1Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.

2Toronto General Hospital Research Institute, University Health Network (UHN), Toronto, Ontario, Canada.

3Department of Physiology,

4Department of Medicine, and

5Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.

Address correspondence to: Jessica Yue, 7-21 Medical Sciences Building, Department of Physiology, University of Alberta, Edmonton, Alberta, Canada T6G2H7. Phone: 780.248.5804; Email: jessica.yue@ualberta.ca. Or to: Tony Lam, MaRS Centre, 101 College Street, Toronto Medical Discovery Tower, 10th floor, Room 705, Toronto, Ontario, Canada M5G1L7. Phone: 416.581.7880; Email: tony.lam@uhnres.utoronto.ca.

Find articles by Lam, T. in: JCI | PubMed | Google Scholar

First published August 12, 2019 - More info

Published in Volume 129, Issue 9 on September 3, 2019
J Clin Invest. 2019;129(9):3532–3535. https://doi.org/10.1172/JCI130755.
© 2019 American Society for Clinical Investigation
First published August 12, 2019 - Version history

Developing effective treatments for obesity and related metabolic disease remains a challenge. One logical strategy targets the appetite-regulating actions of gut hormones such as incretins. One of these incretins, glucose-dependent insulinotropic polypeptide (GIP), has garnered much attention as a potential target: however, whether it is beneficial to boost or block the action of GIP to promote weight loss remains an unresolved question. In this issue of the JCI, Kaneko and colleagues show that antagonizing GIP signaling in the CNS enhances the weight-reducing effects of leptin in rodents with diet-induced obesity. The authors posit that an increase in circulating intestinally derived GIP, as a consequence of overnutrition, acts in the brain to impair hypothalamic leptin action, resulting in increased food intake and body weight gain. This research advances the idea that multiple GIP signaling pathways and mechanisms exist in the obese state and offers intriguing insights into the antiobesogenic consequences of antagonizing brain GIP action.

Preview pages

Reset
Page preview
3533 Page 3532 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
  • Order Online
  • Print subscription
  • $830
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts